መነሻ › በርኪት ሊምፎማ › ዲስትሪክት ኦፍ ኮሎምቢያ
በዲስትሪክት ኦፍ ኮሎምቢያ ለበርኪት ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለበርኪት ሊምፎማ የሚደረጉ 5 ጥናቶች በዲስትሪክት ኦፍ ኮሎምቢያ ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በዲስትሪክት ኦፍ ኮሎምቢያ ውስጥ ያሉ ከተሞች
Official study text (English)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- MedStar Georgetown University Hospital, Washington D.C.
- Children's National Medical Center, Washington D.C.
ተሳታዮችን በመፈለግ ላይደረጃ 2
366 Days – 46 Years · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT06124157Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- MedStar Georgetown University Hospital, Washington D.C.
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's National Medical Center, Washington D.C.
ተሳታዮችን በመፈለግ ላይደረጃ 2
365 Days · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Children's National Medical Center, Washington D.C.
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ ከ1 እስከ 30 · ሁሉም ጾታዎች · የተሻሻለው በ1 ሴፕቴ 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's National Medical Center, Washington D.C.
ተሳታዮችን በመፈለግ ላይደረጃ 3
365 Days – 25 Years · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT03959085ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።